Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases

NCT06311851 is registered in ClinicalTrials.gov with Pardis Noor Medical Imaging and Cancer Center as lead sponsor.

NCT NCT06311851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06311851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases
Lead sponsor
Pardis Noor Medical Imaging and Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 1, 2025
Completion date
October 1, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, liver metastases, metastatic cancer